Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Infinium PharmachemNSE:INFINIUM -1.94%86 PB Ratio is 2.60 as of Aug. 04, 2026, which is 51% below its 10-year median of 5.26. GuruFocus rates NSE:INFINIUM with a GF Score™ of 86/100 and a GF Value™ of ₹307.27 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,577 Chemicals companies, Infinium Pharmachem ranks worse than 69.5% on this metric.
Infinium Pharmachem Ltd stock PB Ratio (=2.69) is close to 5-year low of 2.46.
The historical rank and industry rank for Infinium Pharmachem's PB Ratio or its related term are showing as below:
NSE:INFINIUM'
s PB Ratio Range Over the Past 10 Years
Min: 2.46 Med: 5.26 Max: 17.72
Current: 2.65
During the past 7 years, Infinium Pharmachem's highest PB Ratio was 17.72. The lowest was 2.46. And the median was 5.26.
NSE:INFINIUM's PB Ratio is ranked worse than 69.5% of 1577
companies
in the Chemicals industry
Industry Median: 1.68
vs NSE:INFINIUM: 2.65
During the past 12 months, Infinium Pharmachem's average Book Value Per Share Growth Rate was 10.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 68.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 80.40% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Infinium Pharmachem was 103.00% per year. The lowest was 68.60% per year. And the median was 84.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Infinium Pharmachem PB Ratio Related Terms
Infinium Pharmachem PB Ratio Historical Data
* Premium members only.
The historical data trend for Infinium Pharmachem's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Infinium Pharmachem's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infinium Pharmachem PB Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Infinium Pharmachem's PB Ratio distribution charts can be found below:
* The bar in red indicates where Infinium Pharmachem's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Infinium Pharmachem (NSE:INFINIUM) has a PB Ratio of 2.60 as of Aug. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Infinium Pharmachem and its competitors. This is 51% below median its historical median of 5.26. Over the past decade, Infinium Pharmachem's PB Ratio has ranged from 2.46 to 17.72. According to the industry distribution chart, Infinium Pharmachem ranks #1096 out of 1577 companies in the Chemicals industry, placing it in the top 69.5%.
Is Infinium Pharmachem's PB Ratio too high?
Infinium Pharmachem's current PB Ratio of 2.60 is 51% below median its 10-year median of 5.26. Over the past 10 years, this metric has ranged from a low of 2.46 to a high of 17.72. The Chemicals industry median PB Ratio is 1.68. Infinium Pharmachem's value of 2.60 is 54.8% above this industry median. Based on the distribution chart, Infinium Pharmachem ranks #1096 out of 1577 companies in the Chemicals industry, which is below the industry midpoint. Overall, Infinium Pharmachem has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Infinium Pharmachem's PB Ratio compare to DOW?
According to the Chemicals industry distribution chart, Infinium Pharmachem ranks #1096 out of 1577 companies for PB Ratio. This places Infinium Pharmachem in the lower half of its industry. The industry median PB Ratio is 1.68. Infinium Pharmachem's value of 2.60 is 54.8% above this benchmark. Historically, Infinium Pharmachem's own PB Ratio has ranged from 2.46 to 17.72 over the past decade. While the company's 10-year median is 5.26 vs. the industry median of 1.68, Infinium Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Chemicals company?
The median PB Ratio among Chemicals companies is 1.68, based on 1,577 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinium Pharmachem's current PB Ratio of 2.60 is 54.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Infinium Pharmachem and its competitors. For the Chemicals industry, the median PB Ratio is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinium Pharmachem's current PB Ratio is 2.60, which is 51% below median its own 10-year median of 5.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinium Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Infinium Pharmachem (NSE:INFINIUM) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹307.27, compared to a current price of ₹202.00 — trading 34.3% below its estimated fair value. The current PB Ratio is 2.60, which is 51% below median its 10-year median of 5.26 and 54.8% above the Chemicals industry median of 1.68. Infinium Pharmachem's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Infinium Pharmachem (NSE:INFINIUM), the current PB Ratio is 2.60 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Infinium Pharmachem (NSE:INFINIUM) Overvalued in 2026?
Based on GuruFocus' analysis, Infinium Pharmachem stock appears to be undervalued.
The current stock price of ₹202.00 is trading 34.3% below its estimated GF Value™ of ₹307.27.
GuruFocus considers Infinium Pharmachem to be Significantly Undervalued.
Key valuation signals for NSE:INFINIUM:
PB Ratio: 2.60 (51% below median its 10-year median of 5.26)
GF Value™: ₹307.27 vs. price of ₹202.00 (34.3% below fair value)
Industry Position: 54.8% above the Chemicals median (#1096 of 1577)
No single metric tells the full story. See the NSE:INFINIUM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Infinium Pharmachem Ltd is engaged in the business of manufacturing and supplying Iodine, Iodine Derivatives and Active Pharmaceutical Ingredients (APIs). It provides fully integrated customized services from R & D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals and various other chemicals Industries.
86GF Score
Get the complete analysis for NSE:INFINIUM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFINIUM has been successfully added to your 
